Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) Q2 2025 Earnings | 07/28/2025

About this video

Ekso Bionics Holdings, Inc. posted a challenging Q2 2025, reporting revenue of $2.1 million—a drop of 58% from the same quarter last year, with the decline tied primarily to delayed and deferred Enterprise Health device sales. While the institutional market proved sluggish amidst a pause in customer purchasing, the company achieved over 50% year-over-year growth in its Personal Health products, particularly sales of the Ekso Indego Personal device. Gross profit narrowed to $0.8 million with gross margin compressing to 40% from 53% in Q2 2024, affected by a greater share of lower-margin distribution sales, persistent fixed manufacturing costs, and higher shipping expenses. Service cost improvements and a more robust margin in the personal devices partially offset these headwinds, but not enough to prevent a pronounced year-over-year contraction. The company’s net loss widened to $2.7 million, or $1.24 per share, compared with a loss of $2.4 million, or $1.99 per share, in the prior year. Operational expenditures reflected tight cost management: sales and marketing as well as research and development expenses both edged lower due to payroll and staff adjustments. However, general and administrative costs increased because of fewer expenses being allocated to manufacturing. Cash and restricted cash stood at $5.2 million as of June 30, 2025, down from $6.5 million to start the year, underscoring a need for careful cash discipline and sales execution through the remainder of 2025. Despite these setbacks, management highlighted key progress on strategic initiatives—including being named distributor partners in new orthotics and prosthetics channels and launching AI-enabled features via the NVIDIA Connect program. The new “Ekso Voice Agent” aims to enhance user interaction for the EksoNR platform, while eksoUniversity supports ongoing education for therapists. Although no formal revenue guidance was given, the leadership expressed optimism for a rebound in the second half, expecting delayed Enterprise Health contracts to close and continued momentum in the Personal Health market to drive recovery and future growth. About Inside Ticker: For more expert analysis and real-time updates on Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) and other market movers, follow Inside Ticker and visit http://www.insideticker.com/ for in-depth reports, financial insights, and the latest news on leading companies. #EksoBionics #EKSO #Q22025 #Earnings #FinancialResults #Revenue #NetLoss #GrossMargin #PersonalHealth #EnterpriseHealth #Exoskeletons #MedicalDevices #CashFlow #OperationalExcellence #InsideTicker #AI #Innovation #NVIDIAConnect #Distribution #GrowthStrategy #2025Outlook #Therapy #Rehabilitation #Robotics #HealthcareTech